paclitaxel has been researched along with Invasiveness, Neoplasm in 324 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 14 (4.32) | 18.2507 |
2000's | 102 (31.48) | 29.6817 |
2010's | 185 (57.10) | 24.3611 |
2020's | 23 (7.10) | 2.80 |
Authors | Studies |
---|---|
Asao, Y; Matsuda, H; Miyagawa, K; Nakashima, S; Takayama, S; Xu, F; Yoshida, K; Yoshikawa, M | 1 |
Babal, P; Bohac, M; Burikova, M; Cihova, M; Danisovic, L; Drahosova, S; Janega, P; Krivosikova, L; Kucerova, L; Miklikova, S; Plava, J; Rojikova, L; Smolkova, B; Trnkova, L | 1 |
Ye, Y; Zhang, J; Zhang, R | 1 |
Fujii, T; Gyoten, K; Hayasaki, A; Iizawa, Y; Isaji, S; Kishiwada, M; Komatsubara, H; Kuriyama, N; Maeda, K; Mizuno, S; Murata, Y; Nakagawa, Y; Noguchi, D; Sakurai, H; Shinkai, T; Tanemura, A | 1 |
Chai, OH; Jin, H; Kim, SM; Meng, RY; Nguyen, TV; Park, BH | 1 |
Li, N; Yang, L; Zuo, H | 1 |
Chen, K; Sun, L; Zhang, Y; Zhou, Y | 1 |
Jin, Z; Ma, X; Ni, R; Pan, Y; Wu, Q; Yang, G | 1 |
Er-Bu, A; Tsering, T; Xie, HJ; Zhan-Dui, N; Zhao, J; Zhuo-Ma, D | 1 |
Cen, W; Chen, Z; Huang, D; Liang, F; Su, S; Xia, Y; Zeng, Y; Zhang, X; Zou, J | 1 |
André, F; Arnedos, M; Asselain, B; Chateau-Joubert, S; de Cremoux, P; Dujaric, ME; Lacroix-Triki, M; Marangoni, E; Moindjie, H; Monchecourt, C; Nahmias, C; Nehlig, A; Pierga, JY; Rodrigues-Ferreira, S; Seiler, C; Servant, N | 1 |
Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
Ariake, K; Mitachi, K; Motoi, F; Unno, M | 1 |
Adams, S; Barrios, CH; Chui, SY; Diéras, V; Emens, LA; Henschel, V; Husain, A; Iwata, H; Loi, S; Maiya, V; Molinero, L; Rugo, HS; Schmid, P; Schneeweiss, A; Winer, EP | 1 |
Feng, Y; Hu, L; Huang, Q; Li, L; Li, S; Liu, S; Shi, Q; Su, T; Tan, H; Tao, Z; Yang, H; Zhong, Y | 1 |
Chen, H; Li, J; Li, P; Liu, J; Liu, P; Miao, Y; Wang, R | 1 |
Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
Chuan, Z; Hui, Z; Jiafeng, Z; Miaomiao, Z; Ping, H; Qiongna, D; Xiaojie, J; Yalin, H; Yiting, S | 1 |
Duan, X; Li, Q; Li, X; Li, Y; Shi, L; Wang, Y | 1 |
Byerly, JH; Irie, HY; Port, ER | 1 |
Pei, J; Wang, B; Wang, Z; Yang, X; Zhang, J; Zhao, L | 1 |
Ahmed, N; Bilandzic, M; Escalona, RM; Findlay, JK; Kadife, E; Kannourakis, G; Western, P | 1 |
Gu, Y; Han, M; Li, L; Mi, H; Wang, F; Wang, J; Zhu, M | 1 |
Aghdam, MRF; Francuz, T; Garczorz, W; Kimsa-Furdzik, M; Kosowska, A; Kłych-Ratuszny, A; Simka-Lampa, K | 1 |
Cai, Q; Guo, X; Liu, G; Luo, W; Wang, H; Xiang, T; Xiang, Y; Yuan, C | 1 |
Guan, W; Li, X; Men, T; Wang, F; Xu, G; Xu, X; Zhang, J | 1 |
Chen, C; Dong, Z; Li, Y; Wang, W; Xu, H; Yan, L; Yang, Q; Zhang, L | 1 |
An, Y; Chen, T; Chen, W; Chen, X; Wu, D; Xu, D; Yang, Y; Zhang, X; Zhang, Y | 1 |
Balasubramaniam, J; Chandrasekaran, J; Ravi, A; Sellamuthu, A | 1 |
Adriaenssens, E; Angrand, PO; Bidan, N; Chopin, V; Lagadec, C; Le Bourhis, X; Meignan, S; Toillon, RA; Völkel, P; Winter, M | 1 |
Chang, B; Dahl, DM; George, A; Hu, C; Lee, RJ; Lee-Wu, C; Michaelson, MD; Pham, HT; Sandler, H; Shipley, W; Souhami, L; Swanson, GP; Vuky, J | 1 |
Baldacchino, S; Carlisi, D; Caruana-Dingli, G; De Blasio, A; Debono, J; Degaetano, J; Di Fiore, R; Drago-Ferrante, R; Giordano, A; Grech, G; Pentimalli, F; Saliba, C; Scerri, C; Tesoriere, G; Vento, R | 1 |
Baselga, J; Blau, S; Chan, WY; Dent, R; Espié, M; Im, SA; Isakoff, SJ; Kapp, AV; Kim, SB; Maslyar, DJ; Oliveira, M; Saura, C; Singel, SM; Tan, AR; Wongchenko, MJ | 1 |
Arians, N; Krug, D | 1 |
Altan, B; Asao, T; Azuma, Y; Bai, T; Bao, P; Iijima, M; Kaira, K; Kawabata-Iwakawa, R; Kuwano, H; Mogi, A; Nagashima, T; Nakazawa, S; Nishiyama, M; Obayashi, K; Ohtaki, Y; Onozato, R; Shimizu, K; Watanabe, A; Yajima, T; Yokobori, T | 1 |
Fan, HN; Jiang, QK; Liu, YD; Lu, HL; Qian, Y; Wang, Y; Yang, LY; Zhu, XJ | 1 |
Wu, X | 1 |
Fujii, Y; Hamada, T; Hiyoshi, M; Imamura, N; Nanashima, A; Tsuchimochi, Y; Wada, T; Yano, K | 1 |
Bang, YJ; Boku, N; Chin, K; Hodgson, D; Im, SA; Lee, KW; Liu, YZ; Locker, G; Park, SH; Qin, S; Rha, SY; Rowe, P; Shen, L; Shi, X; Xu, N; Xu, RH | 1 |
Asher, R; Beale, P; Friedlander, M; Kwok, JB; Lee, CK; Park, SB; Selle, F | 1 |
Fujii, K; Ishizuka, S; Saeki, S; Sakata, S; Sasaki, J; Sato, R | 1 |
Han, XD; Li, Z; Liu, MM; Qiu, XL; Ren, Y; Shi, JH; Song, W; Tu, DY; Zhang, J; Zhen, LL | 1 |
Fei, Y; Han, ML; Liang, ZQ; Shen, X; Wang, L; Xiong, YJ; Zhao, YF; Zhu, Y | 1 |
Li, X; Yang, B; Zhai, Z; Zhang, L; Zhang, Y; Zhao, J | 1 |
Chen, C; Chen, Y; Jiang, X; Li, S; Shi, F; Wang, X; Xiong, H; Yan, T; Zhang, W; Zhu, Y | 1 |
Chen, L; Li, J; Liu, Q; Tang, M; Wang, Y; Yu, J | 1 |
Keeratichamroen, S; Lirdprapamongkol, K; Svasti, J | 1 |
Chen, LQ; Fang, WS; Gao, ZG; Huang, W; Jin, MJ; Yu, L; Zhang, ZM | 1 |
Du, P; Han, L; Jiang, K; Liu, X; Zhang, A; Zhang, Q | 1 |
Feng, R; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, Y; Shimada, M | 1 |
Hou, X; Li, R; Tian, B; Wang, X; Wei, F; Yang, L; Zhang, H | 1 |
El-Sokkary, GH; Ismail, IA; Saber, SH | 1 |
Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
El-Tabba', RM; Khajah, MA; Masocha, W; Mathew, P | 1 |
Jiang, H; Ruan, Y; Sun, L; Wu, X; Xu, C; Zhao, J | 1 |
Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF | 1 |
Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M | 1 |
Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
Arasu, V; Esserman, LJ; Gibbs, J; Hylton, NM; Jones, EF; Kornak, J; La Yun, B; Li, E; Li, W; Newitt, DC; Partridge, SC; Wilmes, LJ | 1 |
Buluan, Z; Dongchen, W; Hui, Y; Jin, L; Jinhua, W; Wanzhou, Z; Xi, Y; Yinan, W; Yingchun, W; Zhujun, S | 1 |
Chauhan, N; Chauhan, SC; Hafeez, BB; Jaggi, M; Kashyap, VK; Khan, S; Kumari, S; Mandil, H; Massey, AE; Setua, S; Shetty, AB; Sikander, M; Yallapu, MM | 1 |
Harper, NW; Hodges, KB; Huang, B; O'Connor, KL; Romond, EH; Stewart, RL; Wu, J | 1 |
Chen, CJ; Chen, SL; Chen, TT; Dong, ZY; Wang, WR; Wang, YY; Xu, HN; Yan, L; Yang, QL; Yang, S | 1 |
Duan, T; Luo, C; Sun, F; Wang, M; Wang, Y; Xu, Z; Zhang, J | 1 |
Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N | 1 |
Cao, CN; Gao, L; Luo, JW; Tang, PZ; Xu, GZ; Xu, ZG | 1 |
Keegan, AD; Kingsley, C; Perry, A; Porter, HA; Tran, NL | 1 |
Choi, H; Chow, RH; Hwang, JY; Kim, HH; Kisler, K; Lam, KH; Lee, C; Lee, NS; Lin, MY; Shung, KK; Woo, J; Zhou, Q | 1 |
Bellile, E; Bradford, CR; Byrd, S; Carey, TE; Chepeha, DB; Cordell, KG; Dobrosotskaya, IY; Eisbruch, A; Feng, F; Kumar, B; Maxwell, JH; McHugh, JB; Moyer, JS; Prince, ME; Spector, ME; Teknos, T; Urba, S; Walline, HM; Ward, PD; Wolf, GT; Worden, FP | 1 |
Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
Álvarez, I; Andrés, R; Antón, A; Barnadas, A; Calvo, L; Carabantes, FJ; Carrasco, E; Chacón, JI; Crespo, C; Dorca Ribugent, J; Espinosa, E; González, S; Hernando, B; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, A; Ruiz Borrego, M; Ruiz, A; Salvador Bofill, J; Sánchez-Rovira, P; Seguí-Palmer, MA; Servitja, S | 1 |
Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL | 1 |
Chen, J; Du, QH; Mu, LH; Niu, XH; Wang, P; Zhang, MY | 1 |
Ishiguro, H; Kato, H; Kawaguchi, K; Nakamura, K; Namura, M; Nishimura, T; Nishio, N; Ono, K; Shimada, K; Yamada, H; Yamoto, M; Yoshibayashi, H | 1 |
Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
Ahn, DH; Brahmer, JR; Dahlberg, SE; Gerber, DE; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
Di Cunto, F; Di Renzo, MF; Erriquez, J; Gai, M; Migliardi, G; Musiani, D; Olivero, M; Pavan, S; Torchiaro, E | 1 |
Garbuzenko, OB; Minko, T; Rodriguez-Rodriguez, L; Shah, V; Taratula, O; Taratula, OR | 1 |
Erickson, D; Mak, M | 1 |
Huang, Y; Le, H; Liu, X; Xu, L; Zeng, F; Zhou, J | 1 |
Amadio, G; Masciullo, V; Scambia, G; Stefano, L | 1 |
Hurvitz, SA; Megerdichian, C; Olimpiadi, Y | 1 |
Ghaemmaghamia, F; Karimi-Zarchi, M; Modarress-Gilania, M; Mousavia, AS; Vahidi, S | 1 |
Cong, B; Hao, Y; Peng, C; Sun, Q; Zhao, X; Zhao, Y | 1 |
Chang, CL; Chen, CP; Cheng, JT; Lee, WL; Seow, KM; Tsui, KH; Wang, PH; Wang, SY; Yang, LW; Yen, MS | 1 |
Jia, WH; Li, JD; Luo, RZ; Tu, H; Wan, T; Wang, JH; Yuan, LJ; Yun, JP; Zhang, L; Zheng, M; Zhou, Y | 1 |
Borazanci, E; Von Hoff, DD | 1 |
Ahn, JJ; Badalato, GM; Barlow, LJ; Benson, MC; Decastro, GJ; Ghandour, RA; Holder, DD; Kates, M; McKiernan, JM; Roychoudhury, A | 1 |
Aldinucci, D; Borghese, C; Casagrande, N; Celegato, M; Colombatti, A; Mongiat, M | 1 |
Ding, Y; Fang, J; Li, CL; Li, DS; Yu, AQ; Zeng, Y | 1 |
DiCaudo, DJ; Farhey, Y; Griffing, WL; Martorano, LM; Trotter, SC; Winkelmann, JC; Winkelmann, RR; Yiannias, JA | 1 |
Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D | 1 |
Carrasco, M; Cowden Dahl, KD; Dahl, R; Joseph, S; Li, J; Roy, L; Samyesudhas, SJ | 1 |
Abe, A; Kato, K; Kondo, E; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sueoka, K; Takeshima, N; Umayahara, K; Usami, T; Yamamoto, A | 1 |
Han, N; Li, G; Liu, Z; Yin, J; Zhou, C; Zhou, J | 1 |
Chang, MC; Chen, CA; Cheng, WF; Chiang, YC; Hsieh, CY; Kuo, KT; Lin, HP; Lu, TP | 1 |
Atanaskova Mesinkovska, N; Conic, RZ; Kiracofe, EA; Vidimos, AT | 1 |
Chen, C; Chen, S; Lu, X; Wang, Y; Wang, Z; Wu, Q; Yang, Q; Zhao, Z; Zhu, L | 1 |
Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
Kang, L; Li, J; Li, L; Lu, Y; Ma, W; Mao, J; Song, B; Tao, Y; Yang, B; Zhao, L | 1 |
Akiyama, M; Ito, F; Kitawaki, J; Matsushima, H; Mori, T; Sawada, M; Yamamoto, T | 1 |
Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W | 1 |
Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
Amadio, G; Cosentino, F; Fagotti, A; Paris, I; Petrillo, M; Salutari, V; Scambia, G; Vizzielli, G | 1 |
Andre, F; Burris, HA; Buyse, ME; Cabaribere, D; Dreosti, LM; Hurvitz, SA; Jiang, Z; Lindsay, MA; Liu, D; Mano, MS; Neciosup, SP; Pacaud, LB; Rao, S; Shao, Z; Shen, K; Slamon, D; Taran, T; Toi, M; Tseng, LM; Zhang, Q | 1 |
Aldonza, MB; Bae, SY; Hong, JY; Kim, WK; Lee, SH; Lee, SK; Oh, J; Shin, Y; Song, J | 1 |
Cozma, A; Muntean, V; Simescu, R; Şimon, I; Togănel, RD; Zolog, A | 1 |
Cui, Y; Dong, YY; Jin, H; Lou, G; Xie, K; Zhang, H | 1 |
Cai, J; Chen, S; Dong, Y; Xing, J; Yang, Q; You, H; Zhang, W; Zheng, X | 1 |
Biagioli, E; Bonazzi, C; Buda, A; Chiari, S; Dell'Anna, T; Floriani, I; Gerardi, C; Lissoni, AA; Locatelli, L; Mangioni, C; Milani, R; Signorelli, M | 1 |
Berry, DA; Cirrincione, CT; Golshan, M; Hudis, C; Jasinski, S; Ollila, DW; Sikov, WM; Somlo, G; Weisberg, TF; Winer, E | 1 |
Adhami, VM; Mukhtar, E; Mukhtar, H; Sechi, M | 1 |
Rexer, H | 1 |
Han, F; Yi, X; Zhang, L; Zhou, Y | 1 |
Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
Apor, E; Bishop, K; Charpentier, KP; DiPetrillo, T; Kuritzky, B; Luppe, D; Mantripragada, K; Miner, T; Mitchell, K; Perez, K; Rosati, K; Safran, H | 1 |
Bi, Y; Chen, X; Chen, Y; Cheng, C; Cheng, X; Cui, H; Cui, Y; Guo, J; Guo, S; Hu, X; Jia, J; Jia, Z; Kong, P; Li, G; Li, H; Li, Q; Li, Y; Liang, J; Liu, H; Liu, J; Qian, Y; Shi, R; Song, B; Wang, C; Wang, F; Wang, J; Wang, T; Xi, Y; Xu, E; Yan, T; Yang, B; Yang, J; Zhan, Q; Zhang, L; Zhang, Y; Zhao, Z; Zhou, Y | 1 |
Boxerman, J; Coyle, T; DiPetrillo, T; Donahue, JE; Elinzano, H; Evans, D; Glantz, M; Hebda, N; Kesari, S; Kim, L; Mantripragada, K; Mitchell, KM; Mrugala, M; Pan, E; Piccioni, DE; Rosati, KL; Safran, H; Timothy, K; Yunus, S | 1 |
Cho, HJ; Kim, DK; Kim, HR; Kim, YH; Park, SI; Park, YS | 1 |
Kim, JH; Lee, EJ; Lee, TJ; Nguyen, TM; Park, J; Park, MS; Shin, IW | 1 |
Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
He, X; Huang, J; Liang, X; Wu, K; Wu, Y; Yue, X; Zhang, W; Zhao, P | 1 |
Ali, MS; El-Husseiny, K; Motawei, H | 1 |
Cheng, H; Ding, H; Han, X; Li, A; Liu, Y; Lv, J; Shao, L; Si, X; Sun, L; Sun, Y; Yang, N; Yang, Y; Zhang, XA; Zhu, D | 1 |
Cao, K; Cao, P; Huang, C; Jin, L; Li, X; Luo, Y; Ma, J; Shen, S; Tan, M; Tang, X; Zhou, M | 1 |
Aiba, N; Itoh, G; Iwabuchi, Y; Kohyama, A; Kuriyama, S; Shibata, H; Tanaka, M; Yashiro, M | 1 |
Au Yeung, CL; Co, NN; Kwan, K; Kwan, SY; Leung, CS; Li, Y; Lu, ES; Lu, KH; Mok, SC; Schmandt, R; Tsuruga, T; Wong, KK; Yeung, TL | 1 |
Li, S; Zheng, L | 1 |
Beriwal, S; Boisen, MM; Edwards, RP; Kelley, JL; Lesnock, JL; Richard, SD; Zorn, KK | 1 |
Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
Ameri, A; Khoshbakht Ahmadi, H; Mortazavi, N; Novin, K | 1 |
Abdi, R; Alikhasi, A; Amouzegar-Hashemi, F; Esmati, E; Kalaghchi, B | 1 |
Choi, HG; Jeon, CK; Kang, HR; Kim, SH; Lim, SJ | 1 |
Ishiguro, M; Iwamoto, A; Nishidoi, H; Shibata, S; Tada, Y; Takaya, S; Yamaguchi, Y; Yamashiro, Y | 1 |
Kan, X; Li, Q; Li, Y; Liu, Y; Luo, Y; Ma, Z; Na, D; Su, B; Wang, C; Wang, L; Wang, P; Zhang, G; Zhang, Y; Zhu, X | 1 |
de Graaf, H; de Groot, SM; Drooger, JC; Erdkamp, FL; Hamberg, P; Heijns, JB; Honkoop, A; Imholz, AL; Jager, A; Kroep, JR; Linn, SC; Portielje, JE; Sleijfer, S; Ten Tije, AJ; van Leeuwen-Stok, AE; van Rossum-Schornagel, QC; van Tinteren, H | 1 |
Bassi, N; Brivio, S; Cadamuro, M; Caslini, C; Fabris, L; Indraccolo, S; Massani, M; Nardo, G; Novelli, E; Rosato, A; Sambado, L; Spagnuolo, G; Spirli, C; Stecca, T; Strazzabosco, M | 1 |
Cho, Y; Chun, KH; Kang, H; Kim, HY; Kim, SJ; Song, J; Yim, YS | 1 |
Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW | 1 |
Castro, MG; Doherty, R; Lowenstein, PR; Wilson, TJ; Zamler, DB | 1 |
Liu, M; Wang, Y; Xiao, X; Xiusheng, H | 1 |
Chen, J; Feng, J; Gao, X; Jiang, T; Kang, T; Wei, D; Wei, X; Yao, J; Zhu, Q | 1 |
Li, B; Ren, A; Sun, H; Tang, W; Xiao, H | 1 |
Adiwijaya, B; Cibula, D; Coleman, RL; Czibere, A; Del Campo, JM; Gladieff, L; Harter, P; Hilpert, F; Hirte, H; Kubasek, W; Liu, JF; MacBeath, G; Moyo, V; Naumann, RW; Nering, R; Pearlberg, J; Poveda, AM; Pujade-Lauraine, E; Raspagliesi, F; Ray-Coquard, I; Riahi, K; Selle, F; Siena, S; Tabah-Fisch, I; Vergote, I | 1 |
Fang, P | 1 |
Hoshino, H; Hosoda, Y; Kakita, N; Kawada, J; Kim, Y; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T; Yamasaki, M | 1 |
Anderson, CB; DeCastro, GJ; Ghandour, R; Matulay, JT; McKiernan, JM; Robins, DJ; Sui, W | 1 |
Chen, S; Dong, Y; Meng, T; Ojima, I; Wang, C; Xing, Y; You, H; Zheng, X | 1 |
Ehrlich, BE; England, A; Moore, LM; Rimm, DL | 1 |
Arbini, AA; Greco, M; Marra, E; Moro, L | 1 |
Basu, S; Chelala, C; Crook, T; Danovi, SA; Gangeswaran, R; Harada, T; Holliday, D; Jones, LJ; Lara, R; Lemoine, NR; Manson-Bishop, C; Mein, CA; Pardo, O; Smith, P; Tomlinson, V; Yuan, M | 1 |
Chen, Q; Lin, ZQ; Tan, YT; Wang, LJ; Zhang, BZ; Zhang, X | 1 |
Anthony, CT; Lyons, JM; Thomson, JL; Woltering, EA | 1 |
Choi, IS; Choi, JH; Chung, HC; Hong, YS; Kang, WK; Kim, SY; Lee, JJ; Lee, KH; Lee, YY; Song, HS; Woo, IS | 1 |
Gagnon, PJ; Galderisi, C; Holland, JM; Page, BR | 1 |
Foad, I; Hussein, T; Margergis, M; Mostafa, E; Sharawy, I | 1 |
Chakrabarty, S; Hu, X; Liu, G | 1 |
Heney, NM; Kaufman, DS; Sandler, HM; Shipley, WU; Tanguay, S; Toonkel, LM; Wallace, HJ; Winter, KA; Zietman, AL | 1 |
Besson, P; Gillet, L; Le Guennec, JY; Roger, S; Tran, TA; White, E | 1 |
Barlési, F; Berard, H; Chouaïd, C; Corre, R; Fournel, P; Le Caer, H; Marin, B; Tillon, J; Vergnenègre, A; Vernejoux, JM | 1 |
Bassi, P; Bongiovanni, L; Cappa, E; D'Agostino, D; Gardi, M; Pinto, F; Racioppi, M; Sacco, E; Totaro, A; Volpe, A | 1 |
Dong, P; Jiang, AC; Li, L; Wang, H; Xu, C; Xu, W | 1 |
Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
Carey, MS; D'Souza, DP; Hammond, JA; Harle, IA; Kwon, JS; Lupe, K; Radwan, JS | 1 |
Banik, NL; George, J; Ray, SK | 1 |
Alós, L; Caballero, M; Campayo, M; Grau, JJ; Jansa, S; Monzo, M; Vargas, M | 1 |
Fox, MJ; Gentry, ER; Goldblatt, EM; Gryaznov, SM; Herbert, BS; Shen, C | 1 |
Chakrabarty, S; Liu, G; Patmasiriwat, P; Promkan, M | 1 |
Bajorin, DF; Iasonos, A; Maluf, FC; Milowsky, MI; Mironov, S; Nanus, DM; Regazzi, A; Riches, J; Shi, W | 1 |
Blumenschein, G; Esmaeli, B; Ginsberg, LE; Phan, L; Phan, R; Williams, MD | 1 |
Chen, ZG; Choi, M; El-Naggar, AK; Khuri, FR; Muller, S; Papadimitrakopoulou, VA; Saba, NF; Shin, DM; Shin, HJ; Tighiouart, M | 1 |
Dietz, A; Mekonnen, B; Mozet, C; Stumpp, P | 1 |
Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
Bond, VK; Im, DD; Matsuo, K; Rosenshein, NB | 1 |
Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
Han, L; Jia, Z; Kang, CS; Mei, M; Pu, PY; Ren, Y; Wang, GX; Yao, Z; Yuan, XB; Zhou, X | 1 |
Chiu, CY; Huang, CC; Lo, CP; Shyur, LF | 1 |
Liu, P; Wang, A; Yang, M; Zhang, B; Zhang, X | 1 |
Aramendía, JM; Arbea, L; Aristu, JJ; Cambeiro, M; Espinós, J; Gaztañaga, M; Jurado, M; Martínez-Monge, R | 1 |
Cui, X; Giuliano, A; Kuiatse, I; Lee, AV; Pan, J; Wang, J | 1 |
Batchu, RB; Bryant, CS; Chamala, S; Haider, M; Kumar, S; Morris, R; Pal, J; Potti, RB; Prasad, M; Qazi, AM; Semaan, A; Seward, S; Shah, J; Shammas, MA; Steffes, C; Weaver, DW | 1 |
Boyle, GM; Clements, JA; Dong, Y; Loessner, D; Parsons, PG; Stephens, C; Tan, OL; Walpole, C | 1 |
Deguchi, T; Fujita, Y; Hamada, N; Ito, M; Kitamoto, A; Kojima, K; Kojima, T; Kondo, S; Nozawa, Y; Ohhashi, R; Sato, A | 1 |
Atkins, CD | 1 |
Degeest, K; Filiaci, VL; Hanjani, P; Mannel, RS; Miller, BE; Powell, MA; Rose, PG; Susumu, N; Ueland, FR | 1 |
Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S | 1 |
Charlson, JA; Dankle, SK; Fuller, CK; Russell, TJ | 1 |
Chung, HH; Kang, SB; Kim, K; Kim, MJ; Kim, YH; Lee, JY; Park, NH; Song, YS | 1 |
Adams, S; Bauer, JA; Chakravarthy, AB; Donach, M; Formenti, SC; Goldberg, JD; Hochman, T; Lymberis, S; Muggia, F; Pietenpol, JA; Schneider, RJ; Singh, B; Spicer, D | 1 |
Grigsby, PW; Schwarz, JK; Wahab, S | 1 |
Song, ST | 1 |
Chang, HL; Donahoe, PK; Li, X; MacLaughlin, DT; Nicolaou, F; Pieretti-Vanmarcke, R; Wei, X | 1 |
Huang, W; Lin, Q; Wei, H; Yang, C; Zhang, H | 1 |
Chen, D; Ding, LJ; Ren, XC; Teng, XD; Xia, AL; Xia, HP; Xu, ST; Xue, DB; Zhang, SJ | 1 |
Hasegawa, T; Hidaka, T; Ishizawa, S; Nakashima, A; Nomoto, K; Saito, S; Takano, Y; Tsuneyama, K | 1 |
Chen, W; Kreike, B; Liu, G; Meng, F; Miller, FR; Sethi, S; Wu, G; Zhang, H | 1 |
Hong, GY; Jeong, YI; Lee, E; Lee, HC; Lee, SJ; Oh, JS | 1 |
Chang, HR; Chen, PN; Chu, SC; Hsieh, YS; Hung, TW; Lian, JD; Sun, YS; Wu, SW; Yang, SF | 1 |
Barlow, LJ; Benson, MC; Laudano, MA; Mann, MJ; McKiernan, JM; Petrylak, DP | 1 |
Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M | 1 |
Davidson, NE; Geyer, CE; Jeong, JH; Kaufman, PA; Mamounas, EP; Martino, S; Perez, EA; Romond, EH; Suman, VJ; Wolmark, N | 1 |
Ceccacci, I; Maneschi, F; Manicone, A; Pane, C; Perugini, A; Simeone, A | 1 |
Beck, T; Camara, O; du Bois, A; Fasching, PA; Fett, W; Harbeck, N; Hasmüller, S; Höss, C; Kahlert, S; Konecny, GE; Kreienberg, R; Kühn, T; Lebeau, A; Loibl, S; Mehta, KM; Müller, V; Stickeler, E; Untch, M; von Minckwitz, G | 1 |
Courtneidge, SA; Elia, L; Heynen-Genel, S; Price, JH; Quintavalle, M | 1 |
Aggarwal, BB; Chaturvedi, MM; Park, B; Sung, B; Yadav, VR | 1 |
Culine, S; Demery, ME; Pouessel, D; Thézenas, S | 1 |
Alishekevitz, D; Benayoun, L; Bertolini, F; Bril, R; Gingis-Velitski, S; Loven, D; Munster, M; Shaked, Y; Voloshin, T | 1 |
Fujiwara, H; Hosoi, N; Koeda, K; Konosu, M; Sase, M; Taguchi, M; Tamasawa, Y; Tsukahara, T; Ushio, A; Wakabayashi, G | 1 |
Ha, SW; Kang, SB; Kim, HJ; Kim, JH; Kim, JW; Park, NH; Song, C; Song, S; Song, YS; Wu, HG | 1 |
Kanto, S; Konishi, S; Sakamoto, K; Uehara, M; Yokoyama, D; Yoshino, K | 1 |
Bell-McGuinn, KM; Brogi, E; Elie, BT; Garfall, AL; Joyce, JA; Kester, JC; Olson, OC; Shree, T; Simpson, K; Zabor, EC | 1 |
Deguchi, T; Fujita, Y; Ito, M; Kato, T; Kojima, T; Nakane, K; Nozawa, Y | 1 |
Chang, TC; Chou, HH; Hong, JH; Huang, YT; Lai, CH; Lee, SP; Tsai, CS; Wang, CC | 1 |
Cao, J; Gong, Y; Jin, K; Li, G; Li, Z; Sun, X; Teng, L; Teng, X; Wang, H; Yu, X; Zhang, J; Zheng, Y | 1 |
Campos, FC; Cecchini, AL; Cecchini, R; Colado-Simão, AN; Herrera, AC; Panis, C; Victorino, VJ | 1 |
Chaisarn, P; Prueksaritanond, N; Yanaranop, M | 1 |
Kim, BG; Kim, YC; Lee, JH | 1 |
Fan, L; Huang, X; Lu, Y; Ma, D; Ma, Q; Rao, Y; Wang, C; Wang, H; Xia, X; Yang, J | 1 |
Cohen, M; Delie, F; Petignat, P; Ribaux, P | 1 |
Ali, A; Anbalagan, M; Bu, Y; Carrier, L; Hangauer, D; Jones, RK; Marsden, CG; Rowan, BG; Sheng, M | 1 |
Mei, Q; Wang, M; Wang, X; Wang, Y; Wang, Z; Yang, Z; Zhang, X; Zhao, H | 1 |
Drage, MG; Haddad, RI; Lichtman, AH; Shah, SM | 1 |
Eitaki, M; Inanami, O; Meike, S; Yamamori, T; Yasui, H | 1 |
Ieda, N; Pirovano, C; Siesto, G; Vitobello, D | 1 |
Auranen, A; Carpén, O; Grénman, S; Hynninen, J; Lavonius, M; Oksa, S | 1 |
An, SS; Christudass, CS; Fabry, B; Getzenberg, RH; Kim, JJ; Lee, DY; Mooney, SM; Rajagopalan, K; Shiraishi, T; Terada, N; Veltri, RW; Yin, B | 1 |
Aparicio, S; Chafe, SC; Dedhar, S; Lock, FE; Lou, Y; McDonald, PC; Ostlund, C; Serrano, I; Supuran, CT; Winum, JY | 1 |
Erickson, D; Mak, M; Reinhart-King, CA | 1 |
Baron, R; Binder, A; Hilpert, F; Pfisterer, J; Schattschneider, J; Wasner, G | 1 |
Beckett, L; DeVere-White, R; Folkins, AK; Gandour-Edwards, R; Lara, PN; LaSalle, JM; Li, Y; Meyers, FJ | 1 |
Ishihara, A; Ishiodori, H; Koga, Y; Kudo, S; Nakamura, T; Ochiai, T; Ogata, K; Ohchi, T | 1 |
Asaumi, Y; Hara, T; Hirano, M; Kikkawa, H; Kikuchi, T; Murakami, N; Nozawa, H; Takizawa, M; Uno, Y | 1 |
Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE | 1 |
Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I | 1 |
Greene, MA; Malias, MA | 1 |
Kunstfeld, R; Michaelis, U; Naujoks, K; Petzelbauer, P; Teifel, M; Umek, W; Wickenhauser, G; Wolff, K | 1 |
Cao, Y; Han, R; Liu, HY; Wang, F; Xu, SF | 1 |
Achard, JL; Amat, S; Body, G; Bougnoux, P; Chollet, P; Curé, H; Dauplat, J; Fétissof, F; Kwiatkowski, F; Penault-Llorca, F | 1 |
Amano, Y; Chiba, K; Egi, Y; Fujii, A; Goto, N; Hayashi, K; Kataoka, H; Katayama, K; Kondo, T; Nakajima, M; Ohtsuki, M; Oshita, K; Uehata, M | 1 |
Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J | 1 |
Cetina, L; Chanona, G; de la Garza, J; Dueñas-Gonzalez, A; Gómez, E; González-Enciso, A; López-Graniel, C; Mariscal, I; Mohar, A; Montalvo, G; Rivera, L | 1 |
Dang, C; Seidman, AD | 1 |
Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T | 1 |
Atallah, D; Castaigne, D; Dubernard, G; Duvillard, P; Lhommé, C; Morice, P; Pautier, P; Pomel, C; Rey, A | 1 |
Hirakawa, T; Kobayashi, H; Nakano, H; Ogura, T; Okugawa, K; Sonoda, T | 1 |
Egli, F; Jost, L; Moosmann, P; Stahel, RA | 1 |
Van Cutsem, E | 1 |
Rigas, JR | 1 |
Crown, J; O'Leary, M; Ooi, WS | 1 |
Bellone, S; Cannon, MJ; O'Brien, TJ; Pecorelli, S; Roman, JJ; Santin, AD | 1 |
Gossé, F; Raul, F; Schleiffer, R; Schneider, Y; Seiler, N | 1 |
Asmar, L; Berry, WR; Dakhil, SR; Gregurich, MA; Hathorn, JW; Jackson, DV; Loesch, DM; Newcomb-Fernandez, JK | 1 |
Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
Clynes, M; Gammell, P; Glynn, SA; Heenan, M; Keenan, J; Liang, Y; O'Connor, R | 1 |
Hihara, J; Mizuiri, H; Shimizu, K; Suzuki, T; Tanabe, K; Taomoto, J; Wada, Y; Yoshida, K | 1 |
Dreier, R; Ludwig, T; Oberleithner, H; Ossig, R; Schnaeker, EM; Schneider, SW; Wilhelmi, M | 1 |
Goker, E; Goksel, G; Karabulut, B; Ozdemir, N; Sanli, UA; Sezgin, C; Uslu, R; Zekioglu, O | 1 |
Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F | 1 |
Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H | 1 |
Lamph, WW; Yen, WC | 1 |
DeConti, RC; Ensley, J; Forastiere, AA; Gibson, MK; Hussain, MH; Li, Y; Murphy, B | 1 |
Bjerkvig, R; Goldbrunner, R; Kerkau, S; Martini, R; Schichor, C; Tonn, JC; Visted, T | 1 |
Chan, FL; Chan, KW; Chua, CW; Glackin, C; Kwok, WK; Lau, TC; Lee, TW; Ling, MT; Wang, X; Wong, YC; Zhang, X; Zhou, C | 1 |
Booser, DJ; Buzdar, AU; Carter, C; Cristofanilli, M; Frye, D; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Pusztai, L; Rivera, E; Rosales, MF; Sahin, AA; Sikov, W; Smith, T; Strom, EA; Symmans, WF; Theriault, RL; Valero, V | 1 |
Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K | 1 |
Amrein, PC; Clark, JR; Colevas, AD; Deschler, DG; Fabian, RL; Finkelstein, DM; McIntyre, JF; Posner, MR; Rocco, JW; Supko, JG; Wang, CC | 1 |
Busby, EM; Carey, D; Divers, SG; Hyatt, MD; Robert, F; Spencer, SA | 1 |
Montie, JE | 1 |
Jin, Y; Kasahara, A; Rino, Y; Sugano, N; Takanashi, Y; Tamagawa, H; Yamamoto, Y; Yoneyama, K | 1 |
Kanemoto, H; Takagi, T; Ueda, N | 1 |
Aida, Y; Honma, K; Okura, M; Tanaka, N; Tanimura, S; Tsutsumi, K; Yamamoto, H | 1 |
Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y | 1 |
Imada, T; Kunisaki, C; Ohshima, T; Ohtsuka, Y; Sato, T; Yamada, R | 1 |
Al-Makhalafi, Z; Al-Mohanna, FA; Baitei, EY; Collison, K; Farid, NR; Shi, Y; Zou, M | 1 |
Aiba, T; Furukawa, K; Igarashi, K; Ikeda, H; Iwamoto, Y; Kuwabara, S; Shibuya, H; Shobugawa, K; Takizawa, K; Tsukioka, S; Waguri, N; Yabe, M; Yoneyama, O | 1 |
Chen, B; Hou, X; Xin, X; Yang, H; Zhang, W; Zou, W | 1 |
Clynes, M; Dowd, A; Dowling, P; Glynn, S; Henry, M; Meleady, P | 1 |
Bajorin, DF; Bochner, BH; Boyle, MG; Donat, SM; Galsky, MD; Herr, HW; Iasonos, A; Mironov, S; Russo, P; Scattergood, J | 1 |
Chan, J; Cheng, GZ; Sun, CD; Wang, LH; Wang, Q; Zhang, W | 1 |
Diestelhorst, A; Dunst, J; Fornara, P; Kühn, R; Kuhnt, T; Müller, AC; Scholz, HJ; Zietman, AL | 1 |
Coia, LR; Feigenberg, SJ; Goldberg, M; Hanlon, AL; Lanciano, R; Langer, C; Millenson, M; Movsas, B; Nicolaou, N | 1 |
Atkins, JN; Bearden, JD; Crowley, JJ; Dakhil, SR; Dunphy, FR; Gandara, DR; Giguere, JK; Hesketh, PJ; Kelly, K; McCoy, J; Weiss, GR | 1 |
Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG | 1 |
Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E | 1 |
Bralet, MP; Chebib, A; Gholam, D; Hauteville, D; Jasmin, C | 1 |
Fraig, M; Halushka, PV; Klein, J; Moussa, O; Riker, JM; Watson, DK | 1 |
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F | 1 |
Géczi, L | 1 |
Cheung, ALM; Lau, CK; Lee, TK; Leung, SCL; Ling, MT; Wang, Q; Wang, X; Wong, YC; Zhang, X | 1 |
Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S | 1 |
Morita, R; Nishikawa, M; Okuda, T; Sakata, C; Tokuhara, T | 1 |
Georgoulias, V; Kalbakis, K; Kalykaki, A; Kouroussis, C; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L; Vardakis, N | 1 |
Furukawa, T; Hirai, I; Hirai, Y; Kawago, M; Kiyoi, M; Kokawa, Y; Naito, K; Nakamura, R; Okamura, Y; Ota, F; Oura, S; Shimizu, Y; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
Hosono, Y; Maruyama, K; Motoyama, S; Okuyama, M; Saito, R | 1 |
Burt, HM; Gleave, ME; Hadaschik, BA; Jackson, J; So, AI; Sowery, RD; ter Borg, MG | 1 |
Clynes, M; Henry, M; Keenan, J; Meleady, P; Murphy, L | 1 |
Hayakawa, S; Sato, S; Takano, T; Wagazuma, S; Yajima, A | 1 |
Stearns, ME; Wang, M | 2 |
De Baetselier, P; De Braekeleer, J; Dewit, J; Schirrmacher, V; Verschueren, H | 1 |
Bower, JH; Muenter, MD | 1 |
Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H | 1 |
Khansur, T; Malamud, F; Thigpen, T; Vance, R | 1 |
Höyhtyä, M; Hujanen, E; Puistola, U; Turpeenniemi-Hujanen, T; Westerlund, A | 1 |
Béhar, A; Brun, MD; Chauvin, FF; Feuilhade de Chauvin, F; Hille, D; Maurel, A; Oulid-Aissa, D; Pujade-Lauraine, E | 1 |
Barrett, JC; Baserga, R; Dunn, SE; Ehrlich, M; Hawkins, R; Reiss, K; Sharp, NJ; Solomon, G | 1 |
Antoine, EC; Khayat, D | 1 |
Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S | 1 |
Hait, WN; Liao, J; Medina, DJ; Vassil, AD; Yang, GY; Yang, JM | 1 |
Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
Barillari, G; Carlei, D; Cereseto, A; Ciccolella, C; Ensoli, B; Monini, P; Palladino, C; Sgadari, C; Stürzl, M; Toschi, E; Yarchoan, R | 1 |
Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y | 1 |
Cleary, I; Clynes, M; Connolly, L; Liang, Y; McDonnell, S; Meleady, P | 1 |
Dinney, CP; Inoue, K; Izawa, J; Karashima, T; Kedar, D; Kim, SJ; McConkey, DJ; Millikan, R; Perrotte, P; Shuin, T; Slaton, JW; Sweeney, P; Yoshikawa, C | 1 |
Ando, A; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y | 1 |
Appert, H; Howard, J; Iwamura, T; Liu, B; Staren, E | 1 |
Han, R; Lei, X; Liu, H | 1 |
Ryan, DP; Willett, CG | 1 |
21 review(s) available for paclitaxel and Invasiveness, Neoplasm
Article | Year |
---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
An update on the pharmacotherapy for endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Practice Guidelines as Topic; Radiography; Randomized Controlled Trials as Topic | 2013 |
nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Survival Rate; Treatment Outcome | 2014 |
Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Chemotherapy, Adjuvant; Drug Therapy, Combination; Esophageal Motility Disorders; Female; Humans; Immunohistochemistry; Middle Aged; Myositis; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Raynaud Disease; Risk Assessment; Scleroderma, Systemic; Treatment Outcome | 2016 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Survivin | 2015 |
[Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cervix Uteri; Female; Fluorouracil; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Uterine Cervical Neoplasms | 2008 |
New therapeutical approaches for non muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Humans; Hyaluronic Acid; Immunotherapy; Mitoxantrone; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
[Therapeutic options in sinunasal adenoid cystic carcinomas--a case report and review].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Combined Modality Therapy; Endoscopy; Female; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Orbit; Paclitaxel; Paranasal Sinus Neoplasms; Pterygopalatine Fossa; Radiotherapy, Adjuvant; Skull Neoplasms; Sphenoid Bone; Sphenoid Sinus; Surgery, Computer-Assisted; Tomography, X-Ray Computed | 2009 |
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kidney; Kidney Function Tests; Neoplasm Invasiveness; Paclitaxel; Randomized Controlled Trials as Topic; Urologic Neoplasms; Urothelium | 2012 |
The treatment of advanced gastric cancer: new findings on the activity of the taxanes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Current treatment options for endometrial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Differentiation; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Receptor, ErbB-2; Risk Factors; Survival Analysis; Trastuzumab | 2004 |
[Successful removal of T4 lung cancer with left atrial invasion after induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiac Surgical Procedures; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pneumonectomy | 2005 |
[Modern chemotherapy of invasive bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2007 |
[Chemotherapy of uterine endometrial cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Invasiveness; Paclitaxel | 1995 |
The role of paclitaxel in the management of patients with carcinoma of the cervix.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Female; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms | 1997 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
66 trial(s) available for paclitaxel and Invasiveness, Neoplasm
Article | Year |
---|---|
Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.
Topics: Aged; Aged, 80 and over; Albumins; Arteries; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Vascular Neoplasms | 2021 |
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Double-Blind Method; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cystectomy; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Paclitaxel; Radiation Injuries; Trastuzumab; Treatment Outcome; Urethra; Urinary Bladder Neoplasms | 2017 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Patient Selection; Placebos; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; Risk Assessment; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
[Radiochemotherapy improves failure-free survival in stage III endometrial cancer : Final results of the PORTEC-3 trial].
Topics: Brachytherapy; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies | 2017 |
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Phthalazines; Piperazines; Proportional Hazards Models; Remission Induction; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2017 |
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Neurotoxicity Syndromes; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Physicians; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Survival Rate; Young Adult | 2017 |
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Heart Diseases; Humans; Injections, Subcutaneous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2018 |
Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Topics: Adult; Aged; Area Under Curve; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Diffusion Magnetic Resonance Imaging; Drug Administration Schedule; Echo-Planar Imaging; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies; Trastuzumab; Treatment Outcome; Tumor Burden | 2019 |
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2019 |
Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV-positive and HPV-negative locally advanced squamous cell carcinoma of the oropharynx.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Human papillomavirus 6; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organ Preservation; Oropharyngeal Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Pulse Therapy, Drug; Radiotherapy, High-Energy; Risk Assessment; Serologic Tests; Survival Rate; Time Factors; Treatment Outcome | 2014 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Nodes; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Risk Assessment; Survival Analysis; Treatment Outcome | 2013 |
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Muscle Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Baseline tumour measurements predict survival in advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2013 |
Response to neoadjuvant chemotherapy with paclitaxel and cisplatin in locally advanced cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Tumor Burden; Uterine Cervical Neoplasms | 2013 |
Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Albumins; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Treatment Failure; Urinary Bladder Neoplasms | 2014 |
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Sirolimus; Survival Analysis; Trastuzumab; Treatment Outcome; Young Adult | 2015 |
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Female; Humans; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2015 |
[Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Ke
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Europe; Germany; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; United States; Vinblastine | 2015 |
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2016 |
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Polyglutamic Acid; Radiotherapy, Adjuvant; Single-Blind Method; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; United States | 2018 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2016 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Concurrent Chemoradiation with Weekly Paclitaxel and Cisplatin for Locally Advanced Cervical Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Iran; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Remission Induction; Uterine Cervical Neoplasms | 2016 |
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Rate; Trastuzumab | 2016 |
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemoradiotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Survival Rate | 2016 |
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2016 |
Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Albumins; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kaplan-Meier Estimate; Male; Nanoparticles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur | 2009 |
Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Female; Humans; Male; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Paclitaxel; Urethra; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2009 |
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Patient Compliance; Time Factors; Treatment Outcome; Uterine Cervical Neoplasms | 2010 |
Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinosarcoma; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Program Evaluation; Risk Assessment; Survival Analysis; Treatment Outcome; Uterine Neoplasms | 2010 |
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.
Topics: Adult; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy; Chronic Disease; Cisplatin; Diarrhea; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Lymph Nodes; Middle Aged; Nausea; Neoplasm Invasiveness; Organs at Risk; Paclitaxel; Prospective Studies; Radiotherapy, Intensity-Modulated; Tumor Burden; Uterine Cervical Neoplasms; Vesicovaginal Fistula | 2011 |
A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; BCG Vaccine; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Paclitaxel; Treatment Failure; Urinary Bladder Neoplasms | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Leukopenia; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Neutropenia; Paclitaxel; Receptors, Estrogen; Treatment Outcome | 2012 |
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Receptor, ErbB-2; Remission Induction; Survival Rate; Time Factors; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Remission Induction; Survival Rate; Trastuzumab; Treatment Outcome; Young Adult | 2011 |
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2013 |
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate.
Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Risk Assessment; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome | 2003 |
Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Prostatic Neoplasms; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome | 2005 |
Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Rate; Treatment Outcome | 2005 |
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Paclitaxel; Prospective Studies; Risk Assessment; Survival Rate; Urologic Neoplasms | 2007 |
Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pneumonectomy; Probability; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2007 |
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Probability; Prognosis; Risk Factors; Survival Analysis; Topotecan | 2006 |
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States | 2006 |
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors | 1996 |
The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Female; Flavonoids; Humans; Infusions, Intravenous; Lymphatic System; Middle Aged; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Taxoids; Water-Electrolyte Balance | 1997 |
238 other study(ies) available for paclitaxel and Invasiveness, Neoplasm
Article | Year |
---|---|
Rotenoids and flavonoids with anti-invasion of HT1080, anti-proliferation of U937, and differentiation-inducing activity in HL-60 from Erycibe expansa.
Topics: Cell Differentiation; Cell Proliferation; Convolvulaceae; Enzyme Precursors; Fibrosarcoma; Flavonoids; Gelatinases; HL-60 Cells; Humans; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Plant Extracts; Rotenone; Tumor Cells, Cultured; U937 Cells | 2007 |
Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Transformation, Neoplastic; Doxorubicin; Female; Humans; Mesenchymal Stem Cells; Mice; Mice, SCID; Neoplasm Invasiveness; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Long non-coding RNA (LncRNA) SNHG7/ Eukaryotic translation initiation factor 4 gamma 2 (EIF4G2) involves in the malignant events of ovarian cancer cells with paclitaxel resistant.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4G; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; PTEN Phosphohydrolase; RNA, Long Noncoding; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2021 |
Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Forkhead Box Protein M1; Glycogen Synthase Kinase 3 beta; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction; Triterpenes; Ursolic Acid | 2021 |
Arborinine suppresses ovarian cancer development through inhibition of LSD1.
Topics: Acridines; Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; China; Cisplatin; Epithelial-Mesenchymal Transition; Female; Histone Demethylases; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Ovary; Paclitaxel; Xenograft Model Antitumor Assays | 2022 |
Micro ribonucleic acid-448 regulates zinc finger e-box binding homeobox 1 to inhibit the growth of breast cancer cells and increase their sensitivity to chemotherapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Homeobox; Humans; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Zinc Finger E-box-Binding Homeobox 1; Zinc Fingers | 2022 |
Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Topics: Actins; Animals; Cell Adhesion; Cell Growth Processes; Cell Movement; Cytoskeleton; Disease Models, Animal; Drug Synergism; Ethnopharmacology; Female; Humans; Matrix Metalloproteinases; MDA-MB-231 Cells; Medicine, Chinese Traditional; Mice; Myotonin-Protein Kinase; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; rho-Associated Kinases; Signal Transduction; Triple Negative Breast Neoplasms | 2023 |
Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer.
Topics: A549 Cells; Animals; Apoptosis; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Dequalinium; Down-Regulation; Drug Carriers; Drug Liberation; Extracellular Matrix; Humans; Lung Neoplasms; Mice; Micelles; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Xenograft Model Antitumor Assays | 2019 |
Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Drug Carriers; Drug Liberation; Humans; Hyaluronic Acid; Lung Neoplasms; Mice; Nanoparticles; Neoplasm Invasiveness; Paclitaxel; Selenium; Xenograft Model Antitumor Assays | 2019 |
Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.
Topics: Aneuploidy; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cytokinesis; DNA, Neoplasm; Drug Resistance, Neoplasm; Gene Expression Profiling; Heterografts; Humans; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Paclitaxel; Randomized Controlled Trials as Topic; RNA Interference; Spindle Apparatus; Taxoids; Time-Lapse Imaging; Tumor Suppressor Proteins | 2019 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
Conversion surgery for positive peritoneal washing cytology in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Cytodiagnosis; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Peritoneum; Treatment Outcome | 2019 |
Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Drug Delivery Systems; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Oligopeptides; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Spheroids, Cellular; Tissue Distribution | 2019 |
Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Hippo Signaling Pathway; Humans; MAP Kinase Kinase Kinases; Membrane Proteins; Metformin; Mice, Inbred BALB C; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Serine-Threonine Kinases; Protein Transport; Signal Transduction; Tamoxifen; Transcription Factors; Tumor Suppressor Proteins; YAP-Signaling Proteins | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Implication of hsa_circ_0028007 in reinforcing migration, invasion, and chemo-tolerance of nasopharyngeal carcinoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Humans; Male; MicroRNAs; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Nose; Paclitaxel | 2020 |
The enhanced treatment efficacy of invasive brain glioma by dual-targeted artemether plus paclitaxel micelles.
Topics: Animals; Artemether; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Glioma; Mice; Mice, Inbred ICR; Micelles; Molecular Targeted Therapy; Neoplasm Invasiveness; Paclitaxel | 2020 |
PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Bcl-2-Like Protein 11; Biomarkers, Tumor; Cell Line, Tumor; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Protein Kinase C-theta; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; CELF Proteins; Cell Line, Tumor; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Female; Fructose-Bisphosphatase; Gene Knockdown Techniques; Genes, Reporter; Humans; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; RNA Stability; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Triple Negative Breast Neoplasms; Up-Regulation | 2020 |
TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Benzamides; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Invasiveness; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; STAT3 Transcription Factor; Tissue Inhibitor of Metalloproteinase-2; Transfection | 2020 |
Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line, Transformed; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Proteins; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2020 |
Sitagliptin Modulates the Response of Ovarian Cancer Cells to Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Cell Survival; Dipeptidyl Peptidase 4; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Phosphothreonine; Proto-Oncogene Proteins c-akt; RNA, Messenger; Sitagliptin Phosphate | 2020 |
The novel ZEB1-upregulated protein PRTG induced by Helicobacter pylori infection promotes gastric carcinogenesis through the cGMP/PKG signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cisplatin; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Databases, Genetic; Female; Gene Expression Regulation, Neoplastic; Helicobacter Infections; Helicobacter pylori; Host-Pathogen Interactions; Humans; Male; Membrane Proteins; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Protein Kinase Inhibitors; Second Messenger Systems; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2021 |
Overexpressed COL5A1 is correlated with tumor progression, paclitaxel resistance, and tumor-infiltrating immune cells in ovarian cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type V; Databases, Genetic; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Tumor Microenvironment; Up-Regulation | 2021 |
MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carrier Proteins; Cell Movement; Cell Proliferation; Databases, Genetic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MCF-7 Cells; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Paclitaxel | 2021 |
CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway.
Topics: Aged; Albumins; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CCL26; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2021 |
An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Quassins; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2021 |
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms; Vimentin; Zebrafish | 2021 |
Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Topics: Antineoplastic Agents, Phytogenic; Breast; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Microtubule-Associated Proteins; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Phosphoproteins; Signal Transduction; SOXB1 Transcription Factors; Triple Negative Breast Neoplasms | 2017 |
High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; RNA, Small Interfering; Stathmin; Survival Rate | 2017 |
Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Janus Kinases; Models, Biological; Neoplasm Invasiveness; Paclitaxel; Phenanthrenes; Signal Transduction; STAT3 Transcription Factor; Tongue Neoplasms | 2017 |
Effect of metformin combined with chemotherapeutic agents on gastric cancer cell line AGS.
Topics: Apoptosis; Cell Line, Tumor; Cell Migration Assays; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Metformin; Neoplasm Invasiveness; Paclitaxel; Stomach Neoplasms; Time Factors | 2017 |
A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Splenic Artery | 2017 |
Long-term complete response to carboplatin plus paclitaxel combined with bevacizumab in a patient with metastatic spindle cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Carcinoma; Drug Administration Schedule; Humans; Lung Neoplasms; Lymphatic Metastasis; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pleural Neoplasms; Proteinuria; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2017 |
MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer.
Topics: Animals; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Insulin Receptor Substrate Proteins; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction | 2017 |
A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Cathepsin L; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Signal Transduction | 2018 |
Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-κB Signaling.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Female; Human Umbilical Vein Endothelial Cells; Humans; Leupeptins; MCF-7 Cells; Mice, Inbred C57BL; Neoplasm Invasiveness; NF-kappa B; Paclitaxel; Phenotype; Proteasome Inhibitors; Signal Transduction | 2018 |
miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer.
Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaempferols; Lymphatic Metastasis; MCF-7 Cells; Microfilament Proteins; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Buformin; Cell Proliferation; Female; Humans; Hypoglycemic Agents; Neoplasm Invasiveness; Paclitaxel; Uterine Cervical Neoplasms | 2018 |
Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells.
Topics: A549 Cells; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen; Drug Combinations; Drug Resistance, Neoplasm; Extracellular Matrix; Gene Expression Regulation, Neoplastic; Humans; Laminin; Lung Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Phosphatidylinositol 3-Kinases; Proteoglycans; Proto-Oncogene Proteins c-akt; Signal Transduction | 2018 |
Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Stability; Female; Humans; Inhibitory Concentration 50; Mice; Nanoparticles; Neoplasm Invasiveness; Paclitaxel; Particle Size; Serum Albumin, Human; Time Factors; Triple Negative Breast Neoplasms | 2017 |
Effects of miR-200a and FH535 combined with taxol on proliferation and invasion of gastric cancer.
Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Stomach Neoplasms; Sulfonamides | 2018 |
Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro.
Topics: Albumins; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL10; Coculture Techniques; Down-Regulation; Epithelial-Mesenchymal Transition; Fibroblasts; Humans; Interleukin-10; Interleukin-6; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Up-Regulation; Vimentin | 2018 |
Fluorescent magnetic PEI-PLGA nanoparticles loaded with paclitaxel for concurrent cell imaging, enhanced apoptosis and autophagy in human brain cancer.
Topics: Actin Cytoskeleton; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Liberation; Fluorescence; Humans; Magnetite Nanoparticles; Molecular Imaging; Neoplasm Invasiveness; Paclitaxel; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer; Reactive Oxygen Species | 2018 |
Melatonin inhibits breast cancer cell invasion through modulating DJ-1/KLF17/ID-1 signaling pathway.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cadherins; Cell Movement; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Inhibitor of Differentiation Protein 1; MCF-7 Cells; Melatonin; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Deglycase DJ-1; Signal Transduction; Transcription Factors | 2019 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
COL‑3 enhances the anti‑proliferative and pro‑apoptotic effects of paclitaxel in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; MCF-7 Cells; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Tetracyclines | 2019 |
Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; beta-Galactoside alpha-2,3-Sialyltransferase; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Sialyltransferases; Signal Transduction; Transforming Growth Factor beta1; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult | 2019 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
3-acetyl-11-keto-beta-boswellic acid decreases the malignancy of taxol resistant human ovarian cancer by inhibiting multidrug resistance (MDR) proteins function.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Triterpenes | 2019 |
Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Endocytosis; Humans; Membrane Microdomains; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Xenograft Model Antitumor Assays | 2019 |
Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; RNA, Long Noncoding | 2019 |
HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Death; Cell Line, Tumor; Endocytosis; Fluorescence; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Mice; Molecular Targeted Therapy; Nanoparticles; Neoplasm Invasiveness; Neovascularization, Physiologic; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Tumor Microenvironment | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Management of nasopharyngeal adenoid cystic carcinoma.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Combined Modality Therapy; Cranial Nerve Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Paclitaxel; Palliative Care; Retrospective Studies; Treatment Outcome | 2013 |
IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Female; Humans; Insulin Receptor Substrate Proteins; MCF-7 Cells; Neoplasm Grading; Neoplasm Invasiveness; Paclitaxel; Phosphorylation; Signal Transduction; STAT6 Transcription Factor; Transfection | 2013 |
Investigating contactless high frequency ultrasound microbeam stimulation for determination of invasion potential of breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Survival; Female; Humans; Intracellular Space; Neoplasm Invasiveness; Optical Imaging; Paclitaxel; Sound | 2013 |
Propofol inhibits invasion and enhances paclitaxel- induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug.
Topics: Anesthetics, Intravenous; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; In Situ Nick-End Labeling; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Propofol; Snail Family Transcription Factors; Tetrazolium Salts; Thiazoles; Transcription Factors | 2013 |
[A patient with primary breast cancer who responded remarkably well to neoadjuvant chemotherapy with FEC100 followed by Abraxane].
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Hepatocyte Growth Factor; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2014 |
Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascitic Fluid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Dendrimers; Female; Gene Expression; Gonadotropin-Releasing Hormone; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasm Invasiveness; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polypropylenes; Receptors, LHRH; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous; Tumor Cells, Cultured | 2013 |
A serial micropipette microfluidic device with applications to cancer cell repeated deformation studies.
Topics: Automation; Biomechanical Phenomena; Cell Line, Tumor; Cell Shape; Elasticity; Equipment Design; Extracellular Matrix; Humans; Materials Testing; Microfluidics; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Single-Cell Analysis; Stress, Mechanical; Viscosity | 2013 |
Anticancer effects of cinnamic acid in lung adenocarcinoma cell line h1299-derived stem-like cells.
Topics: AC133 Antigen; Adenocarcinoma; Animals; Antigens, CD; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cinnamates; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Lung Neoplasms; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplastic Stem Cells; Paclitaxel; Peptides; Xenograft Model Antitumor Assays | 2013 |
Effect of Smac and Taxol on non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Primers; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mitochondrial Proteins; Neoplasm Invasiveness; Paclitaxel; Plasmids; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cytotoxins; Dose-Response Relationship, Drug; Drug Synergism; Female; Gonadotropin-Releasing Hormone; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH | 2014 |
SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Cell Survival; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; HEK293 Cells; HeLa Cells; Humans; Kaplan-Meier Estimate; Neoplasm Invasiveness; Paclitaxel; Risk Factors; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Topics: AC133 Antigen; Albumin-Bound Paclitaxel; Albumins; Antigens, CD; Antineoplastic Agents; bcl-2-Associated X Protein; Caspases; Cell Line, Tumor; Cell Movement; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Glycoproteins; Humans; Liposomes; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Peptides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Spheroids, Cellular; Up-Regulation | 2014 |
TALEN-mediated Nanog disruption results in less invasiveness, more chemosensitivity and reversal of EMT in Hela cells.
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Survival; Cisplatin; Deoxyribonucleases; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Homeodomain Proteins; Humans; Mice, Nude; Mutation; Nanog Homeobox Protein; Neoplasm Invasiveness; Paclitaxel; RNA Editing; Time Factors; Transfection; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Camptothecin; Case-Control Studies; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Humans; Immunoenzyme Techniques; Irinotecan; Male; Matrix Metalloproteinase 7; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Syndecan-1; Tumor Cells, Cultured | 2014 |
ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Peptides; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Para-Aortic Bodies; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
miR-107 activates ATR/Chk1 pathway and suppress cervical cancer invasion by targeting MCL1.
Topics: Antineoplastic Agents, Phytogenic; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Down-Regulation; Female; Humans; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Paclitaxel; Protein Kinases; Signal Transduction; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Establishment of a New Ovarian Cancer Cell Line CA5171.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cisplatin; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phenotype; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Tumor Suppressor Protein p53 | 2015 |
Treatment of invasive squamous cell carcinomas in an open Clagett window.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Debridement; Empyema; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Paclitaxel; Pleural Cavity; Pleural Neoplasms; Thoracostomy | 2015 |
MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; RNA Interference; Semaphorins; Signal Transduction; Transfection | 2015 |
MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway.
Topics: Breast Neoplasms; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Stem Cells; Paclitaxel; Receptor, Notch1; Signal Transduction | 2015 |
Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kinesins; MAP Kinase Signaling System; Middle Aged; Myosins; Neoplasm Invasiveness; Paclitaxel | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Paclitaxel | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Remission Induction; Survival Rate | 2015 |
Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; TOR Serine-Threonine Kinases; Triterpenes | 2015 |
Primary peritoneal serous psammocarcinoma: a case report.
Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calcinosis; Carboplatin; Chemotherapy, Adjuvant; Colectomy; Cytoreduction Surgical Procedures; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
shRNA Depletion of cIAP1 Sensitizes Human Ovarian Cancer Cells to Anticancer Agent-Induced Apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2014 |
Salvianolic acid A reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Caffeic Acids; Cell Movement; Cell Shape; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gene Knockdown Techniques; Humans; Lactates; MCF-7 Cells; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Paclitaxel | 2015 |
Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer: Validity of Pathological Response as Surrogate Endpoint of Survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Uterine Cervical Neoplasms; Young Adult | 2015 |
Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Topics: Acetylation; Animals; Binding Sites; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Flavonoids; Flavonols; Male; Microtubule-Associated Proteins; Microtubules; Molecular Docking Simulation; Neoplasm Invasiveness; Nuclear Proteins; Paclitaxel; Prostatic Neoplasms; Protein Binding; Protein Conformation; Protein Processing, Post-Translational; Protein Stability; Signal Transduction; Surface Plasmon Resonance; Time Factors; Tubulin; Tubulin Modulators | 2015 |
[Effect of down-regulation of Oct4 gene on biological characteristics of MDA-MB-231 breast cancer stem cells].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Culture Media, Serum-Free; Down-Regulation; Female; Gene Knockdown Techniques; Humans; Mice; Neoplasm Invasiveness; Neoplastic Stem Cells; Octamer Transcription Factor-3; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Transfection; Tumor Burden | 2015 |
Caveolin-1 regulates cell apoptosis and invasion ability in paclitaxel-induced multidrug-resistant A549 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Caveolin 1; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Neoplasm Invasiveness; Paclitaxel | 2015 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; China; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Genomics; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2016 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Topics: Adenoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Tumor Stem Cell Assay | 2016 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells.
Topics: Adult; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fluorescent Antibody Technique; Follow-Up Studies; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lymphatic Metastasis; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NADH, NADPH Oxidoreductases; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; RNA, Small Interfering; STAT3 Transcription Factor; Survival Rate; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2016 |
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Remission Induction; Survival Rate | 2016 |
ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Promoter Regions, Genetic; Survival Rate; Tumor Cells, Cultured | 2016 |
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lymphatic Metastasis; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Tumor Cells, Cultured | 2016 |
Identification of anti-cancer chemical compounds using Xenopus embryos.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Benzofurans; Carbolines; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Evaluation, Preclinical; Embryo Loss; Embryo, Nonmammalian; Female; Gastrulation; Glioma; Indole Alkaloids; Melanoma, Experimental; Mice; Microtubules; Neoplasm Invasiveness; Paclitaxel; Podophyllotoxin; Rats; Receptors, CXCR4; Xenograft Model Antitumor Assays; Xenopus | 2016 |
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.
Topics: Adipocytes; Apoptosis; Apoptotic Protease-Activating Factor 1; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Exosomes; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Stromal Cells | 2016 |
Effect of Combined Treatment Using Wilfortrine and Paclitaxel in Liver Cancer and Related Mechanism.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Paclitaxel; RNA, Messenger | 2016 |
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2016 |
Butyrate-mediated acquisition of chemoresistance by human colon cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; bcl-X Protein; Butyrates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; Hydroxamic Acids; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel | 2016 |
[A Case of Drug-Induced Lung Injury Associated with Paclitaxel plus Bevacizumab Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Lung Injury; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pulse Therapy, Drug; Respiration Disorders; Steroids | 2016 |
Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Epithelial-Mesenchymal Transition; Estrogens; Female; Gene Expression; Gene Expression Profiling; Humans; Inflammation Mediators; Liver; Liver Neoplasms; Mice; Neoplasm Invasiveness; NF-kappa B; Paclitaxel | 2016 |
Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Humans; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; S100 Calcium-Binding Protein A4; Sumoylation; Xenograft Model Antitumor Assays | 2016 |
Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Transplantation; Nuclear Proteins; Paclitaxel; Phenotype; Prognosis; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Stomach Neoplasms | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotaxis; Cyclic GMP-Dependent Protein Kinase Type I; Dacarbazine; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neoplastic Stem Cells; Neurons; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Stem Cells; Temozolomide | 2016 |
Overexpression of miR-422a inhibits cell proliferation and invasion, and enhances chemosensitivity in osteosarcoma cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Binding Sites; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Osteosarcoma; Paclitaxel; RNA Interference; Transforming Growth Factor beta2 | 2016 |
Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Breast; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Epithelial Cell Adhesion Molecule; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Rats, Sprague-Dawley | 2017 |
Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplastic Stem Cells; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Phenotype; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Transfection; Twist-Related Protein 1; Up-Regulation | 2017 |
Internal Mammary Misfortune.
Topics: Bone Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Dose Fractionation, Radiation; Female; Humans; Lymphatic Irradiation; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Radiosurgery; Radiotherapy, Adjuvant; Sternum | 2017 |
[A Case of Curatively Resected Locally Advanced Cancer of the Pancreatic Body Treated by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Preoperative Intensive Treatment].
Topics: Aged; Albumins; Celiac Artery; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2016 |
SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspase 9; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Spheroids, Cellular; Taxoids; Tumor Cells, Cultured | 2017 |
Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Calcium-Binding Proteins; Cell Movement; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Middle Aged; Neoplasm Invasiveness; Neuronal Calcium-Sensor Proteins; Neuropeptides; Paclitaxel; Prognosis; Receptor, ErbB-2 | 2017 |
Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma.
Topics: Androgens; Apoptosis; Carcinogens; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Cell Transformation, Neoplastic; DNA, Mitochondrial; Drug Resistance, Neoplasm; Ethidium; Humans; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms | 2008 |
Yes-associated protein (YAP) functions as a tumor suppressor in breast.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anoikis; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cytoprotection; Drug Resistance; Epithelium; Gene Deletion; Gene Silencing; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Paclitaxel; Phosphoproteins; Proto-Oncogene Mas; Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2008 |
A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biological Assay; Blood Coagulation; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Female; Fibrin; Fluorouracil; Humans; Methotrexate; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Thrombin; Vincristine | 2008 |
Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Follow-Up Studies; Hemangiosarcoma; Humans; Immunohistochemistry; Laryngeal Neoplasms; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2009 |
Calcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells.
Topics: Breast Neoplasms; Cell Adhesion; Cell Death; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Extracellular Space; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Invasiveness; Paclitaxel; Receptors, Calcium-Sensing; Survivin | 2009 |
Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Mitosis; NAV1.5 Voltage-Gated Sodium Channel; Neoplasm Invasiveness; Paclitaxel; Signal Transduction; Sodium Channels; Tubulin Modulators | 2009 |
MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Laryngeal Neoplasms; Neoplasm Invasiveness; Paclitaxel; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel | 2009 |
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth.
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Situ Nick-End Labeling; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2009 |
Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Head and Neck Neoplasms; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Nuclear Proteins; Paclitaxel; Palliative Care; Polymorphism, Single Nucleotide; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel.
Topics: Actins; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Female; Fluorescent Antibody Technique; Focal Adhesions; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Oligonucleotides; Oligopeptides; Paclitaxel; Telomerase; Xenograft Model Antitumor Assays | 2009 |
BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; BRCA1 Protein; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Invasiveness; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survivin | 2009 |
Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cheek; Cranial Nerve Neoplasms; Facial Neoplasms; Humans; Magnetic Resonance Imaging; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Trigeminal Nerve Diseases | 2009 |
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclooxygenase 2; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hyperplasia; Ifosfamide; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Precancerous Conditions; Prognosis; Survival Rate | 2009 |
Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2010 |
Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Combined Modality Therapy; Dendrimers; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Transfection | 2010 |
Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Breast Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2; Dose-Response Relationship, Drug; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lactones; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; NF-kappa B; Paclitaxel; Reactive Oxygen Species; Sesquiterpenes; Time Factors; Tumor Burden; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Female; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Oligodeoxyribonucleotides; Ovarian Neoplasms; Paclitaxel; STAT3 Transcription Factor; Transfection | 2010 |
Sustained c-Jun-NH2-kinase activity promotes epithelial-mesenchymal transition, invasion, and survival of breast cancer cells by regulating extracellular signal-regulated kinase activation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Dedifferentiation; Cell Lineage; Cell Movement; Cell Survival; Cell Transformation, Neoplastic; Enzyme Activation; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Insulin Receptor Substrate Proteins; JNK Mitogen-Activated Protein Kinases; Mesoderm; Mice; Neoplasm Invasiveness; Paclitaxel; Proto-Oncogene Proteins c-fos; Transcription Factor AP-1; Up-Regulation | 2010 |
Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells.
Topics: Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA, Neoplasm; E2F1 Transcription Factor; Epithelial Cells; Female; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Neoplasm Invasiveness; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Retinoblastoma Protein; S Phase; Sulfoxides; Thiocyanates; Wound Healing | 2010 |
Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma.
Topics: Animals; Cell Aggregation; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epithelium; Female; Fibronectins; Humans; Integrin alpha5beta1; Kallikreins; Mice; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Vitronectin | 2010 |
MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
Topics: Animals; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Hormones; Humans; Male; MicroRNAs; Molecular Sequence Data; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Sequence Homology, Amino Acid | 2010 |
Optimal chemotherapy for high-risk early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2010 |
[Primary urothelial carcinoma with sarcomatous transformation of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms | 2010 |
Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Facial Neoplasms; Follow-Up Studies; Hemangiosarcoma; Humans; Immunohistochemistry; Male; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2010 |
Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Hysterectomy; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome; Tumor Burden; Uterine Cervical Neoplasms | 2011 |
[Practice and consideration on neoadjuvant therapy for early breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Burden | 2010 |
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Fibrosarcoma; Head and Neck Neoplasms; Humans; Neoplasm Invasiveness; Neoplasms; Ovarian Neoplasms; Paclitaxel; Receptors, Peptide; Receptors, Transforming Growth Factor beta | 2011 |
[Effect of combined use of PDTC and paclitaxel on proliferation and invasion of human breast cancer cell line MCF-7].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Neoplasm Invasiveness; NF-kappa B; Paclitaxel; Pyrrolidines; Thiocarbamates | 2010 |
[Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Menopause; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Uterine Neoplasms | 2010 |
Ovarian squamous cell carcinoma which metastasized 8 years after cervical conization for early microinvasive cervical cancer: a case report.
Topics: Adult; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Conization; Cyclin-Dependent Kinase Inhibitor p16; DNA, Viral; Female; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Palliative Care; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Neoplastic; Radiotherapy, Adjuvant; Reoperation; Time Factors; Uterine Cervical Neoplasms; Watchful Waiting | 2011 |
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Doxorubicin; Humans; Mice; Mitogen-Activated Protein Kinase 12; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phenanthrenes; Phosphatidylinositol 3-Kinase; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2011 |
Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of CT-26 colon carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Synergism; Humans; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Invasiveness; Paclitaxel; Particle Size; Surface Properties; Tretinoin | 2011 |
Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; HEK293 Cells; Humans; Kidney Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred ICR; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Paclitaxel; Silybin; Silymarin; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2011 |
Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Predictive Value of Tests; Preoperative Care; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Salpingectomy | 2012 |
A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Calmodulin-Binding Proteins; Cell Line, Tumor; Cell Surface Extensions; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase Inhibitor Proteins; DNA Primers; Flow Cytometry; Fluorescent Antibody Technique; Humans; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; Paclitaxel; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2011 |
Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Diterpenes; Enzyme Inhibitors; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Inflammation; Leukemia; Molecular Structure; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Paclitaxel; Phenanthrenes; Signal Transduction; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice.
Topics: Animals; Cell Movement; Cells, Cultured; Female; Humans; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasm Invasiveness; Neoplasms, Experimental; Paclitaxel | 2011 |
[A case of advanced adenocarcinoma of esophagogastric junction with severe esophageal invasion effectively treated by chemoradiotherapy using paclitaxel and cisplatin, and S-1 after chemoradiotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2012 |
[A case of pagetoid carcinoma of the breast in nearly complete response by primary systemic therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Paget's Disease, Mammary; Trastuzumab | 2011 |
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
Topics: Animals; Antineoplastic Agents; Cathepsins; Cell Line, Tumor; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; Female; Lung Neoplasms; Macrophages; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Neoplasm Invasiveness; Paclitaxel | 2011 |
ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Protein c-ets-1; Up-Regulation | 2012 |
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Risk; Salvage Therapy; Survival Rate; Treatment Failure; Uterine Cervical Neoplasms; Young Adult | 2012 |
Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
Topics: Adult; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Estrogen Receptor alpha; Estrogens; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; JNK Mitogen-Activated Protein Kinases; M Phase Cell Cycle Checkpoints; MicroRNAs; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Paclitaxel; Signal Transduction; Transfection | 2012 |
Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients.
Topics: Adult; Antineoplastic Agents; Antioxidants; Breast Neoplasms; Carcinoma, Ductal, Breast; Cytokines; Doxorubicin; Female; Humans; Inflammation; Lipid Peroxidation; Malondialdehyde; Middle Aged; Neoplasm Invasiveness; Nitric Oxide; Oxidative Stress; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Treatment Outcome | 2012 |
The efficacy of neoadjuvant paclitaxel-carboplatin chemotherapy followed by radical hysterectomy compared to radical hysterectomy alone in bulky stage IB2-IIA cervical cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Uterine Cervical Neoplasms | 2012 |
Thymosin β10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production.
Topics: Actins; Adenoviridae; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Movement; Cisplatin; DNA Primers; Female; Flow Cytometry; Fluorescein-5-isothiocyanate; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Genetic Therapy; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Thymosin | 2012 |
Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Blotting, Western; Caspase 9; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured; Tumor Stem Cell Assay; Wnt Proteins | 2012 |
Anti-KDEL-coated nanoparticles: a promising tumor targeting approach for ovarian cancer?
Topics: Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Membrane Proteins; Molecular Targeted Therapy; Nanoparticles; Neoplasm Invasiveness; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Protein Sorting Signals | 2012 |
Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Topics: Acetamides; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dasatinib; Drug Synergism; Estrogen Receptor alpha; Female; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neoplasm Invasiveness; Neoplasm Micrometastasis; Neovascularization, Pathologic; Paclitaxel; Peptidomimetics; Pyridines; Pyrimidines; Receptor, ErbB-2; Receptors, Progesterone; src-Family Kinases; Thiazoles; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cystadenocarcinoma, Serous; Diterpenes; Epoxy Compounds; Female; Gene Expression Regulation, Enzymologic; Humans; Matrix Metalloproteinase 7; Matrix Metalloproteinases, Secreted; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Phenanthrenes; Promoter Regions, Genetic; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Metastatic human papillomavirus-positive nasopharyngeal carcinoma with an unusual pattern of aggressive hematogenous spread.
Topics: Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biomarkers, Tumor; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Diagnosis, Differential; Drug Administration Schedule; Fatal Outcome; Fluorodeoxyglucose F18; Fluorouracil; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Immunohistochemistry; Laryngoscopy; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Papillomavirus Infections; Positron-Emission Tomography; Pulmonary Artery; Radiopharmaceuticals; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic; Thrombophilia; Tomography, X-Ray Computed; Vascular Neoplasms | 2012 |
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Movement; Cisplatin; Cytoskeleton; Etoposide; Guanine Nucleotide Exchange Factors; Humans; Myosin Light Chains; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Rho Guanine Nucleotide Exchange Factors; rho-Associated Kinases; rhoA GTP-Binding Protein; Stomach Neoplasms; Vincristine | 2012 |
Surgical outcomes of robotic radical hysterectomy after neoadjuvant chemotherapy for locally advanced cervical cancer: comparison with early stage disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Dose Fractionation, Radiation; Epirubicin; Feasibility Studies; Female; Humans; Hysterectomy; Ifosfamide; Laparoscopy; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Robotics; Safety; Treatment Outcome; Uterine Cervical Neoplasms; Vagina | 2013 |
Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Nucleus; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Inhibitory Concentration 50; Keratin-18; Keratin-19; Keratin-8; Male; Mice; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplastic Stem Cells; Paclitaxel; Phenylurea Compounds; Spheroids, Cellular; Stem Cell Niche; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial Cells; Female; Humans; Microfluidic Analytical Techniques; Microfluidics; Microtubules; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Paclitaxel | 2013 |
Docetaxel-induced nail changes--a neurogenic mechanism: a case report.
Topics: Afferent Pathways; Arm; Brachial Plexus; Breast Neoplasms; Docetaxel; Efferent Pathways; Female; Humans; Middle Aged; Motor Neurons; Nail Diseases; Neoplasm Invasiveness; Neural Conduction; Neurologic Examination; Neurons, Afferent; Paclitaxel; Paralysis; Parasympathetic Nervous System; Sensory Thresholds; Skin; Sympathetic Nervous System; Taxoids; Vibration | 2002 |
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Receptor, ErbB-2; Survival Analysis; Urinary Bladder Neoplasms | 2002 |
[A case of advanced gastric cancer with invasion of pancreas effectively treated by combined chemotherapy of TS-1 and paclitaxel (TXL)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2002 |
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Floxuridine; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2002 |
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin | 2002 |
Aggressive multimodality treatment of invasive thymic carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Postoperative Care; Radiotherapy, Adjuvant; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed | 2003 |
Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Capsules; Cations; Cell Division; Endothelium, Vascular; Humans; Liposomes; Melanoma, Experimental; Mice; Mice, SCID; Mitotic Index; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Tumor Cells, Cultured | 2003 |
Anti-invasion and anti-angiogenesis effect of taxol and camptothecin on melanoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion; Cell Movement; Chick Embryo; Collagenases; Humans; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Tumor Cells, Cultured | 2003 |
Effect of Wf-536, a novel ROCK inhibitor, against metastasis of B16 melanoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Cell Line, Tumor; Cell Movement; Cell Survival; Enzyme Inhibitors; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Paclitaxel; Protein Serine-Threonine Kinases; Pyridines; rho-Associated Kinases | 2003 |
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells | 2003 |
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymph Nodes; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2003 |
[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur; Treatment Outcome | 2003 |
Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Treatment Outcome | 2003 |
In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2004 |
Polyploidisation of metastatic colon carcinoma cells by microtubule and tubulin interacting drugs: effect on proteolytic activity and invasiveness.
Topics: Cell Division; Cell Line, Tumor; Colchicine; Colonic Neoplasms; Humans; Matrix Metalloproteinase 7; Microtubules; Neoplasm Invasiveness; Paclitaxel; Polyploidy; Tissue Plasminogen Activator; Tubulin | 2004 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Adhesion; Cell Movement; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Invasiveness; Paclitaxel; Phenotype; Selection, Genetic | 2004 |
[Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Alopecia; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Duodenal Neoplasms; Humans; Jaundice, Obstructive; Leukopenia; Lymph Nodes; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Stomach Neoplasms | 2004 |
Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.
Topics: Animals; Cytoplasmic Vesicles; Dogs; Exocytosis; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma, Amelanotic; Microtubules; Neoplasm Invasiveness; Paclitaxel; Subcellular Fractions; Tumor Cells, Cultured | 2004 |
Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays | 2004 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Invasiveness; Nitriles; Paclitaxel; Skin Neoplasms; Sternum; Triazoles | 2005 |
The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Umbilical Veins | 2005 |
The brain slice chamber, a novel variation of the Boyden Chamber Assay, allows time-dependent quantification of glioma invasion into mammalian brain in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Astrocytes; Brain Neoplasms; Coculture Techniques; Dose-Response Relationship, Drug; Extracellular Matrix; Frontal Lobe; Glioma; Neoplasm Invasiveness; Organ Culture Techniques; Paclitaxel; Parietal Lobe; Swine; Vincristine | 2005 |
Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Epithelial Cells; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mesoderm; Neoplasm Invasiveness; Nuclear Proteins; Paclitaxel; Prostatic Neoplasms; Transcription Factors; Transfection; Twist-Related Protein 1; Up-Regulation | 2005 |
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan | 2005 |
[A case of advanced gastric cancer effectively treated by combined chemotherapy of TS-1 and paclitaxel].
Topics: Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Lymph Node Excision; Male; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Splenic Neoplasms; Stomach Neoplasms; Tegafur | 2005 |
[Effective treatment of unresectable advanced gastric cancer by TS-1-based chemotherapy with a sequential combination of cisplatin (CDDP) and paclitaxel (PTX)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Liver Neoplasms; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Colon, Transverse; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Humans; Ileus; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms | 2005 |
[Low-dose weekly paclitaxel therapy proved useful for a case of recurrent gastric cancer with clinically latent hepatic cirrhosis].
Topics: Aged; Anastomosis, Roux-en-Y; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrectomy; Humans; Liver Cirrhosis; Male; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2006 |
Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model.
Topics: Animals; Apoptosis; Cell Proliferation; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; RNA Interference; S100 Calcium-Binding Protein A4; S100 Proteins; Thyroid Neoplasms | 2006 |
[A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy].
Topics: Abdominal Wall; Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Radiography, Abdominal; Stomach Neoplasms; Tomography, X-Ray Computed | 2006 |
Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Basigin; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasms, Experimental; Ovarian Neoplasms; Paclitaxel; Plasmids; RNA Interference; RNA, Small Interfering; Transfection | 2007 |
Proteomic analysis of isolated membrane fractions from superinvasive cancer cells.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Movement; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Nuclear Proteins; Paclitaxel; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Transcriptional Activation; Tumor Cells, Cultured; Twist-Related Protein 1 | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Fluorouracil; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms; Survivors | 2007 |
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negativ
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cetuximab; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2007 |
Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Neoplasm Invasiveness; Paclitaxel; Thromboxane-A Synthase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2008 |
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelin A Receptor Antagonists; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays | 2007 |
Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells.
Topics: Apoptosis; Caveolin 1; Cell Movement; Drug Resistance, Neoplasm; Epithelium; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Male; Mesoderm; Molecular Sequence Data; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Protein Binding; Two-Hybrid System Techniques | 2007 |
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms | 2007 |
[Resection of cancer of the cardia enabled by combined treatment with S-1 and paclitaxel after esophageal stenting for impaired patency complicating stage IV gastric cancer - a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cardia; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Paclitaxel; Stents; Stomach Neoplasms; Tegafur | 2007 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2008 |
In vitro evaluation of dose-response curve for paclitaxel in breast cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Evaluation Studies as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Tumor Cells, Cultured | 2007 |
[A case of thoracic esophageal cancer with invasion of the main bronchus in which long-term survival with high quality of life was achieved through chemoradiotherapy, esophageal bypass and then additional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Quality of Life | 2007 |
Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cisplatin; Female; Mice; Mice, Nude; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Reactive Oxygen Species; Taxoids | 2008 |
Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol.
Topics: Animals; Antibody Specificity; Blotting, Western; Bone Neoplasms; Cell Division; Clone Cells; Enzyme-Linked Immunosorbent Assay; Gelatinases; Glycoproteins; Humans; Immunoassay; Immunoblotting; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1994 |
Motility and invasive potency of murine T-lymphoma cells: effect of microtubule inhibitors.
Topics: Animals; Cell Movement; Fibroblasts; Fourier Analysis; Leukemia L5178; Lymphoma, T-Cell; Mice; Mice, Inbred DBA; Microtubules; Neoplasm Invasiveness; Nocodazole; Paclitaxel; Tumor Cells, Cultured | 1994 |
Temporary worsening of parkinsonism in a patient with Parkinson's disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Unknown Primary; Paclitaxel; Parkinson Disease | 1995 |
Ovarian cancer cell invasion is inhibited by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Cell Movement; Female; Gelatinases; Humans; Matrix Metalloproteinase 2; Metalloendopeptidases; Microtubules; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Proteins; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-2; Tumor Cells, Cultured | 1997 |
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Adhesion; Cell Division; Codon; Collagen; Culture Media, Conditioned; Female; Humans; Insulin-Like Growth Factor I; Laminin; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Point Mutation; Polymerase Chain Reaction; Precipitin Tests; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 1998 |
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Female; Flupenthixol; Humans; Hydrogen-Ion Concentration; Leukemia P388; Liver Neoplasms; Mechlorethamine; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Survival Rate; Tumor Cells, Cultured; Vincristine | 1999 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Mechanism of paclitaxel activity in Kaposi's sarcoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Movement; Down-Regulation; Growth Inhibitors; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Sarcoma, Experimental; Sarcoma, Kaposi; Tumor Cells, Cultured | 2000 |
[A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Hypercalcemia; Lymph Nodes; Lymphatic Metastasis; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Paclitaxel; Taxoids | 2000 |
Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness.
Topics: Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Integrins; Melphalan; Membrane Glycoproteins; Neoplasm Invasiveness; Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tetraspanin 29; Tumor Cells, Cultured | 2001 |
Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Biopsy; Blood Vessels; Blotting, Northern; Cadherins; Carcinoma, Transitional Cell; Cell Movement; Collagen; Collagenases; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Endothelial Growth Factors; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Interferon-alpha; Interleukin-8; Laminin; Lymphokines; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Paclitaxel; Prognosis; Proteoglycans; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Docetaxel; Female; Humans; Middle Aged; Mixed Function Oxygenases; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids | 2002 |
Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Humans; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phenotype; Proteoglycans; Rhodamine 123; RNA, Neoplasm; Taxoids; Tumor Cells, Cultured | 2001 |
[Anti-invasion activity of several plant-originated anticancer drugs with different mechanism of action].
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Division; Cell Movement; Fibrosarcoma; Harringtonines; Homoharringtonine; Humans; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Paclitaxel; Plant Bark; Plant Roots; Taxus; Tumor Cells, Cultured | 1998 |
Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Gelatinases; Humans; Male; Mice; Mice, SCID; Microbial Collagenase; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Pepsin A; Prostatic Neoplasms; Proteins | 1992 |